Technical analysis of Cardiff Oncology, Inc. (CRDF): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer.
Price Performance
| 1 month | +52.35% |
| 3 months | +11.57% |
| Year-to-date | -51.96% |
| 1 year | -32.84% |
| 3 years | -20.12% |
| 5 years | -80.32% |
52-Week Range
| 52-week High | $3.31 |
| 52-week Low | $0.76 |
| Avg Volume (90d) | 1.3M |
Technical Indicators
| SMA 50 | $1.01 |
| SMA 200 | $1.69 |
| Beta | 1.42 |
| 30-day Volatility (annualised) | 72.9% |
| Price vs SMA 50 | +33.4% |
| Price vs SMA 200 | -20.0% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $2.35 | |
| 2025-11 | $2.28 | -3.0% |
| 2025-12 | $2.81 | +23.2% |
| 2026-01 | $1.75 | -37.7% |
| 2026-02 | $1.94 | +10.9% |
| 2026-03 | $1.62 | -16.5% |
| 2026-04 | $1.73 | +6.8% |
| 2026-05 | $1.90 | +9.8% |
| 2026-06 | $1.30 | -31.6% |
| 2026-07 | $0.86 | -34.2% |
| 2026-08 | $0.99 | +16.2% |
| 2026-09 | $1.35 | +35.9% |
Price
| Price | $1.35 |
| Market Cap | $104M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 3.63 |
| EV / EBITDA | -1.93 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.02 |
| Current Ratio | 3.30 |